Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma-Reference-Cited by-同舟云学术

Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma

Published:2004-08-04 Issue:5 Volume:126 Page:665-674
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Bakkus Marleen H. C.,Bouko Yasmina,Samson Diana,Apperley Jane F.,Thielemans Kris,Camp Benjamin Van,Benner Axel,Goldschmidt Hartmut,Moos Marion,Cremer Friedrich W.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2004.05120.x/fullpdf

Reference46 articles.

1. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome;Attal;New England Journal of Medicine,1996

2. Single versus double autologous stem-cell transplantation for multiple myeloma;Attal;New England Journal of Medicine,2003

3. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies;Aubin;Leukemia,1995

4. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning;Badros;Journal of Clinical Oncology,2002

5. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation;Bakkus;Blood,1992

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in estimating plasma cells in bone marrow: A comprehensive method review;African Journal of Laboratory Medicine;2024-07-11

2. Measurable Residual Disease of Multiple Myeloma: Current Methods and Future Directions;Laboratory Medicine Online;2024-07-01

3. Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future;Cancers;2023-07-20

4. Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications;Frontiers in Oncology;2022-01-26

5. Minimal residual disease in multiple myeloma: current status;Biomarker Research;2021-10-14